Our research reveals that YCWLP exerts therapeutic effects against NASH by inhibiting lipid accumulation and inflammation, which involves the attenuation of pyroptosis via the SHP2/PI3K/NLRP3 pathway. The gene discussed is NLRP3; the disease is metabolic dysfunction-associated steatohepatitis.